- Trials with a EudraCT protocol (34)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
34 result(s) found for: Early psychosis.
Displaying page 1 of 2.
EudraCT Number: 2015-000465-31 | Sponsor Protocol Number: CannaBiD | Start Date*: 2016-06-29 | |||||||||||||||||||||||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||||||||||||||||||||||
Full Title: Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression | |||||||||||||||||||||||||||||||||
Medical condition: Bipolar disorder, current episode depressed | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-005435-87 | Sponsor Protocol Number: FIBHGM-ECNC002-2012 | Start Date*: 2013-02-14 | |||||||||||
Sponsor Name:Fundación para la Investigación Biomédica Hospital Gregorio Marañón | |||||||||||||
Full Title: EFFECT OF ADJUVANT TREATMENT WITH N - ACETYLCYSTEINE DURING 48 WEEKS ON THE LOSS OF GREY SUBSTANCE AND OXIDATIVE METABOLISM IN PATIENTS WITH EARLY ONSET PSYCHOTIC EPISODES: BLIND, PLACEBO-CONTROLLE... | |||||||||||||
Medical condition: PATIENTS WITH EARLY ONSET PSYCHOTIC EPISODES | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000163-32 | Sponsor Protocol Number: NorPEPS | Start Date*: 2017-06-29 |
Sponsor Name:Helse-Bergen HF | ||
Full Title: The Norwegian Prednisolone in Early Psychosis Study - NorPEPS The role of immune-modulating strategies in the treatment of psychosis | ||
Medical condition: Schizophrenia, schizophreniphorm disorder, schizoaffective disorder, psychosis NOS. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002699-98 | Sponsor Protocol Number: CB001-OL | Start Date*: 2015-04-14 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: OxLith: Exploration of the short-term physical and psychological effects of lithium in mood instability | |||||||||||||
Medical condition: Bipolar disorder with current mood instability | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004023-24 | Sponsor Protocol Number: PRETEC-EPO | Start Date*: 2016-12-15 | ||||||||||||||||
Sponsor Name:Copenhagen Affective Disorder research Center (CADIC), Psychiatric Centre Copenhagen, Rigshospitalet | ||||||||||||||||||
Full Title: Effect of erythropoietin (EPO) on cognitive function and frontal lobe activity in patients with bipolar disorder and unipolar depression in remission (PRETEC-EPO) | ||||||||||||||||||
Medical condition: Bipolar disorder and unipolar depression | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-001515-10 | Sponsor Protocol Number: KAR-031 | Start Date*: 2022-12-12 | ||||||||||||||||
Sponsor Name:Karuna Therapeutics | ||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease Deme... | ||||||||||||||||||
Medical condition: Psychosis Associated with Alzheimer’s Disease Dementia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) SK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned) DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002787-32 | Sponsor Protocol Number: RG_19-172 | Start Date*: 2020-11-16 |
Sponsor Name:University of Birmingham | ||
Full Title: Antidepressant for the prevention of DEPression following first episode Psychosis trial | ||
Medical condition: Patients with First Episode Psychosis. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004973-42 | Sponsor Protocol Number: 1289.32 | Start Date*: 2017-11-21 | |||||||||||
Sponsor Name:Boehringer Ingelheim Limited | |||||||||||||
Full Title: A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early inter... | |||||||||||||
Medical condition: attenuated psychosis syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022463-35 | Sponsor Protocol Number: 3.1 | Start Date*: 2011-07-08 |
Sponsor Name:Manchester Mental Health and Social Care Trust | ||
Full Title: The Benefit of Minocycline on Negative Symptoms in Psychosis: Extent and Mechanisms | ||
Medical condition: schizophrenia | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003076-22 | Sponsor Protocol Number: PSY-201401_ESPRIT | Start Date*: 2016-07-07 | ||||||||||||||||
Sponsor Name:Central Institute of Mental Health Mannheim (ZI) | ||||||||||||||||||
Full Title: Multimodal Prevention of First Psychotic Episode – a 2x2-Factorial Randomized Trial investigating the efficacy of Acetylcysteine (ACC) and Integrated Preventive Psychological Intervention (IPPI) in... | ||||||||||||||||||
Medical condition: Clinical High Risk state for developing a first psychotic episode | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001244-15 | Sponsor Protocol Number: D22-P006 | Start Date*: 2023-01-12 |
Sponsor Name:GHU Paris Psychiatrie et Neurosciences | ||
Full Title: Efficiency of a composite personalised care on functional outcome in early psychosis: A Prospective Randomised Controlled Trial - PsyCARE_Trial | ||
Medical condition: early psychosis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2009-015629-35 | Sponsor Protocol Number: R076477SCH3038 | Start Date*: 2009-11-05 |
Sponsor Name:Janssen-Cilag NV/SA | ||
Full Title: Open-label, single arm, interventional study to explore the efficacy and safety of paliperidone ER in the management of patients with acute agitation and/or aggression | ||
Medical condition: Subject presenting with acute agitation and/or agression in the context of psychosis, suspected schizophrenia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000520-14 | Sponsor Protocol Number: NL46653 | Start Date*: 2014-07-31 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: Prednisolone addition for atients with recent onset psychotic disorder: the role of immune-modulating strategies in the treatment of psychosis. | ||
Medical condition: Schizophrenia, schizophreniphorm disorder, schizoaffective disorder, psychosis NOS. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-001573-28 | Sponsor Protocol Number: Uni-Koeln-320 | Start Date*: 2007-11-26 |
Sponsor Name:Universität zu Köln | ||
Full Title: Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial. | ||
Medical condition: Persons at risk of being prodromally symptomatic of psychosis (PAR) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016715-38 | Sponsor Protocol Number: TEAprotocolversion3-12102009FINAL | Start Date*: 2010-02-08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University of Copenhagen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: The TEA Trial- Tolerance and Effect of Antipsychotics in children and adolescents with psychosis An investigator-initiated, phase IV, randomised double-blind multi-centre trial of the benefits and... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: non-organic and non-drug-induced psychosis, meeting the criteria for ICD-10 diagnoses: F20, F22-F29 and F30.2, F31.2, F31.5, F32.3 and F33.3. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001408-39 | Sponsor Protocol Number: SPON1720-19 | Start Date*: 2020-03-31 | |||||||||||
Sponsor Name:Cardiff University | |||||||||||||
Full Title: Treating Anxiety to PrevEnt Relapse in Psychosis (TAPERS): a feasibility trial | |||||||||||||
Medical condition: Psychosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002093-34 | Sponsor Protocol Number: NW-3509/020/III/2021 | Start Date*: 2021-11-12 | |||||||||||||||||||||
Sponsor Name:NEWRON PHARMACEUTICALS SPA | |||||||||||||||||||||||
Full Title: A Phase II/III, multi-center, open-label, extension study to determine the long-term safety, tolerability, and efficacy of evenamide in patients with psychiatric disorders who participated in a pre... | |||||||||||||||||||||||
Medical condition: Patients with psychiatric disorders who participated in a previous trial with evenamide. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005004-13 | Sponsor Protocol Number: NEURAPRO-E FINAL Protocol | Start Date*: 2010-10-14 |
Sponsor Name:Orygen Research Centre | ||
Full Title: Add-on Therapie mit Omega-3 Fettsäuren bei Jugendlichen mit hohem Risiko für Schizophrenie und andere psychotische Störungen: eine Multizentren- Replikationsstudie Omega-3 Fatty Acids for Symptomat... | ||
Medical condition: In view of recent data and after a careful review of potentially neuroprotective treatment options in early psychotic illness, we have decided to replicate the findings of a randomized controlled t... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002406-12 | Sponsor Protocol Number: NL6220204217 | Start Date*: 2019-04-04 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: HAMLETT. Handling Antipsychotic Medication: Long-term Evaluation of Targeted Treatment. A pragmatic single blind RCT of continuation versus discontinuation/ dose reduction of antipsychotic medicati... | ||
Medical condition: HAMLETT compares regular treatment guidelines for patients in remission after a first episode of psychosis, namely continuation with antipsychotic medication for at least one year, with early dose ... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004621-25 | Sponsor Protocol Number: RIS-SCH-4043 | Start Date*: 2006-01-30 | |||||||||||
Sponsor Name:Janssen-Cilag Medical Affairs EMEA | |||||||||||||
Full Title: Is premorbid functioning a predictor of outcome in patients with early onset psychosis treated with Risperdal Consta? | |||||||||||||
Medical condition: Schizophrenia, schizoaffective disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) NL (Completed) BE (Completed) IT (Completed) PT (Completed) GR (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
